Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Shuji Ogino, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Shuji Ogino and Jeffrey Meyerhardt.
Connection Strength

15.093
  1. Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer. Cancer Immunol Immunother. 2021 Sep 16.
    View in: PubMed
    Score: 0.247
  2. Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma. Oncoimmunology. 2021; 10(1):1956173.
    View in: PubMed
    Score: 0.245
  3. Smoking and Incidence of Colorectal Cancer Subclassified by Tumor-Associated Macrophage Infiltrates. J Natl Cancer Inst. 2021 Jul 15.
    View in: PubMed
    Score: 0.244
  4. Tumor Long Interspersed Nucleotide Element-1 (LINE-1) Hypomethylation in Relation to Age of Colorectal Cancer Diagnosis and Prognosis. Cancers (Basel). 2021 Apr 22; 13(9).
    View in: PubMed
    Score: 0.240
  5. Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. Clin Cancer Res. 2021 May 15; 27(10):2816-2826.
    View in: PubMed
    Score: 0.237
  6. Coffee Intake and Colorectal Cancer Incidence According to T-Cell Response. JNCI Cancer Spectr. 2020 Dec; 4(6):pkaa068.
    View in: PubMed
    Score: 0.230
  7. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine. 2020 Jul; 57:102860.
    View in: PubMed
    Score: 0.227
  8. Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction. JNCI Cancer Spectr. 2020 Aug; 4(5):pkaa040.
    View in: PubMed
    Score: 0.225
  9. Metabolic Profiling of Formalin-Fixed Paraffin-Embedded Tissues Discriminates Normal Colon from Colorectal Cancer. Mol Cancer Res. 2020 06; 18(6):883-890.
    View in: PubMed
    Score: 0.222
  10. An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer. Br J Cancer. 2020 04; 122(9):1367-1377.
    View in: PubMed
    Score: 0.222
  11. Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer. J Pathol. 2020 04; 250(4):397-408.
    View in: PubMed
    Score: 0.221
  12. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019 04; 111:82-93.
    View in: PubMed
    Score: 0.207
  13. Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells. JNCI Cancer Spectr. 2018 Oct; 2(4):pky058.
    View in: PubMed
    Score: 0.205
  14. Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. J Natl Cancer Inst. 2019 01 01; 111(1):42-51.
    View in: PubMed
    Score: 0.204
  15. The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol. 2018 12; 188(12):2839-2852.
    View in: PubMed
    Score: 0.201
  16. Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res. 2018 11; 6(11):1327-1336.
    View in: PubMed
    Score: 0.200
  17. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer. 2018 11; 103:98-107.
    View in: PubMed
    Score: 0.200
  18. Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 10; 27(10):1227-1230.
    View in: PubMed
    Score: 0.198
  19. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncol. 2018 06 01; 4(6):783-790.
    View in: PubMed
    Score: 0.196
  20. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb; 2(2):pky017.
    View in: PubMed
    Score: 0.196
  21. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 2018; 7(7):e1442999.
    View in: PubMed
    Score: 0.194
  22. Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 04; 27(4):438-445.
    View in: PubMed
    Score: 0.192
  23. Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017 Oct 20; 8(50):87379-87389.
    View in: PubMed
    Score: 0.187
  24. Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue. JAMA Oncol. 2017 Jul 01; 3(7):921-927.
    View in: PubMed
    Score: 0.184
  25. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol. 2017 Jun 01; 35(16):1836-1844.
    View in: PubMed
    Score: 0.182
  26. Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol. 2016 Nov 03; 7(11):e200.
    View in: PubMed
    Score: 0.176
  27. MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. Cancer Immunol Res. 2016 11; 4(11):927-935.
    View in: PubMed
    Score: 0.175
  28. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin Cancer Res. 2016 08 01; 22(15):3841-8.
    View in: PubMed
    Score: 0.168
  29. Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. Ann Surg Oncol. 2016 Mar; 23(3):908-17.
    View in: PubMed
    Score: 0.165
  30. Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clin Cancer Res. 2016 Mar 15; 22(6):1489-98.
    View in: PubMed
    Score: 0.164
  31. Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. Am J Clin Nutr. 2015 Nov; 102(5):1134-41.
    View in: PubMed
    Score: 0.163
  32. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016 12; 65(12):1973-1980.
    View in: PubMed
    Score: 0.162
  33. Post diagnosis diet quality and colorectal cancer survival in women. PLoS One. 2014; 9(12):e115377.
    View in: PubMed
    Score: 0.154
  34. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol. 2015 Apr; 22(4):1226-1235.
    View in: PubMed
    Score: 0.153
  35. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst. 2014 Sep; 106(9).
    View in: PubMed
    Score: 0.152
  36. Response. J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.151
  37. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
    View in: PubMed
    Score: 0.149
  38. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 2014 May 31; 13:135.
    View in: PubMed
    Score: 0.149
  39. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
    View in: PubMed
    Score: 0.143
  40. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013 Aug 07; 105(15):1151-6.
    View in: PubMed
    Score: 0.140
  41. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014 Jun 05; 33(23):2949-55.
    View in: PubMed
    Score: 0.139
  42. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1142-52.
    View in: PubMed
    Score: 0.138
  43. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with ß-catenin (CTNNB1) status. Cancer Res. 2013 Mar 01; 73(5):1600-10.
    View in: PubMed
    Score: 0.136
  44. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013 Apr; 26(4):465-84.
    View in: PubMed
    Score: 0.135
  45. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst. 2013 Jan 16; 105(2):130-40.
    View in: PubMed
    Score: 0.134
  46. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012 Oct 25; 367(17):1596-606.
    View in: PubMed
    Score: 0.133
  47. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. Arch Surg. 2012 Aug; 147(8):715-23.
    View in: PubMed
    Score: 0.131
  48. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 2012 Dec; 48(18):3405-13.
    View in: PubMed
    Score: 0.131
  49. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012 Sep 01; 18(17):4753-63.
    View in: PubMed
    Score: 0.130
  50. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012 Apr 15; 18(8):2257-68.
    View in: PubMed
    Score: 0.127
  51. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst. 2012 Mar 07; 104(5):415-20.
    View in: PubMed
    Score: 0.127
  52. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012 Jun; 19(6):1944-53.
    View in: PubMed
    Score: 0.126
  53. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
    View in: PubMed
    Score: 0.125
  54. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012 Sep 01; 131(5):1169-78.
    View in: PubMed
    Score: 0.125
  55. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One. 2011; 6(9):e25062.
    View in: PubMed
    Score: 0.123
  56. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011 Apr 27; 305(16):1685-94.
    View in: PubMed
    Score: 0.120
  57. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer. 2011 Mar 01; 128(5):1080-94.
    View in: PubMed
    Score: 0.119
  58. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010 Dec; 222(4):350-66.
    View in: PubMed
    Score: 0.117
  59. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011 Apr 01; 117(7):1399-408.
    View in: PubMed
    Score: 0.116
  60. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010 Sep 28; 103(7):1025-33.
    View in: PubMed
    Score: 0.115
  61. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010 May; 176(5):2292-301.
    View in: PubMed
    Score: 0.111
  62. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009 Dec 14; 169(22):2102-8.
    View in: PubMed
    Score: 0.109
  63. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9.
    View in: PubMed
    Score: 0.109
  64. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009 Oct 15; 15(20):6412-20.
    View in: PubMed
    Score: 0.108
  65. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 2010 Feb; 105(2):420-33.
    View in: PubMed
    Score: 0.108
  66. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2765-72.
    View in: PubMed
    Score: 0.108
  67. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
    View in: PubMed
    Score: 0.107
  68. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2513-21.
    View in: PubMed
    Score: 0.107
  69. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol. 2009 Sep 20; 27(27):4591-8.
    View in: PubMed
    Score: 0.107
  70. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009 Nov; 137(5):1609-20.e1-3.
    View in: PubMed
    Score: 0.107
  71. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res. 2009 Jul 15; 15(14):4665-73.
    View in: PubMed
    Score: 0.106
  72. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009 Jul 01; 15(13):4431-8.
    View in: PubMed
    Score: 0.106
  73. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1849-58.
    View in: PubMed
    Score: 0.105
  74. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008 Dec 10; 26(35):5713-20.
    View in: PubMed
    Score: 0.101
  75. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009 Jan; 58(1):90-6.
    View in: PubMed
    Score: 0.101
  76. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol. 2008 Mar; 21(3):245-55.
    View in: PubMed
    Score: 0.096
  77. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007 Sep; 28(9):1985-90.
    View in: PubMed
    Score: 0.092
  78. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia. 2007 Jul; 9(7):569-77.
    View in: PubMed
    Score: 0.092
  79. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37.
    View in: PubMed
    Score: 0.090
  80. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007 Nov; 56(11):1564-71.
    View in: PubMed
    Score: 0.090
  81. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70.
    View in: PubMed
    Score: 0.089
  82. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 May; 6(1):59-65.
    View in: PubMed
    Score: 0.085
  83. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006 Jan; 19(1):59-68.
    View in: PubMed
    Score: 0.083
  84. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6.
    View in: PubMed
    Score: 0.081
  85. Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival. Br J Cancer. 2021 Sep; 125(7):1016-1024.
    View in: PubMed
    Score: 0.061
  86. Discovery and Features of an Alkylating Signature in Colorectal Cancer. Cancer Discov. 2021 Oct; 11(10):2446-2455.
    View in: PubMed
    Score: 0.061
  87. Postdiagnostic dairy products intake and colorectal cancer survival in US males and females. Am J Clin Nutr. 2021 06 01; 113(6):1636-1646.
    View in: PubMed
    Score: 0.060
  88. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. Gut. 2021 Dec; 70(12):2330-2336.
    View in: PubMed
    Score: 0.060
  89. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectr. 2021 Jun; 5(3):pkab034.
    View in: PubMed
    Score: 0.060
  90. Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.060
  91. Simple Sugar and Sugar-Sweetened Beverage Intake During Adolescence and Risk of Colorectal Cancer Precursors. Gastroenterology. 2021 07; 161(1):128-142.e20.
    View in: PubMed
    Score: 0.060
  92. Aspirin Use and Risk of Colorectal Cancer Among Older Adults. JAMA Oncol. 2021 Mar 01; 7(3):428-435.
    View in: PubMed
    Score: 0.059
  93. Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):757-764.
    View in: PubMed
    Score: 0.059
  94. Dairy intake during adolescence and risk of colorectal adenoma later in life. Br J Cancer. 2021 03; 124(6):1160-1168.
    View in: PubMed
    Score: 0.059
  95. Dietary intake of branched-chain amino acids and survival after colorectal cancer diagnosis. Int J Cancer. 2020 Dec 19.
    View in: PubMed
    Score: 0.059
  96. A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer. JNCI Cancer Spectr. 2021 Feb; 5(1):pkaa093.
    View in: PubMed
    Score: 0.058
  97. Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes. JNCI Cancer Spectr. 2021 Feb; 5(1):pkaa089.
    View in: PubMed
    Score: 0.058
  98. The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment. Cancer Immunol Res. 2021 01; 9(1):8-19.
    View in: PubMed
    Score: 0.058
  99. Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020 11; 29(11):2323-2331.
    View in: PubMed
    Score: 0.057
  100. Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin-Stained Sections. Clin Cancer Res. 2020 08 15; 26(16):4326-4338.
    View in: PubMed
    Score: 0.056
  101. No Association Between Vitamin D Supplementation and Risk of Colorectal Adenomas or Serrated Polyps in a Randomized Trial. Clin Gastroenterol Hepatol. 2021 01; 19(1):128-135.e6.
    View in: PubMed
    Score: 0.055
  102. Effect of Supplementation With Marine ?-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial. JAMA Oncol. 2020 Jan 01; 6(1):108-115.
    View in: PubMed
    Score: 0.055
  103. Dietary Intake of Branched-Chain Amino Acids and Risk of Colorectal Cancer. Cancer Prev Res (Phila). 2020 01; 13(1):65-72.
    View in: PubMed
    Score: 0.054
  104. Night-Shift Work Duration and Risk of Colorectal Cancer According to IRS1 and IRS2 Expression. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):133-140.
    View in: PubMed
    Score: 0.054
  105. Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses' Health Study II. Br J Cancer. 2019 07; 121(1):86-94.
    View in: PubMed
    Score: 0.053
  106. Calcium intake and colon cancer risk subtypes by tumor molecular characteristics. Cancer Causes Control. 2019 Jun; 30(6):637-649.
    View in: PubMed
    Score: 0.052
  107. Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells. Cancer Prev Res (Phila). 2019 05; 12(5):283-294.
    View in: PubMed
    Score: 0.052
  108. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
    View in: PubMed
    Score: 0.051
  109. Low-Carbohydrate Diet Score and Macronutrient Intake in Relation to Survival After Colorectal Cancer Diagnosis. JNCI Cancer Spectr. 2018 Nov; 2(4):pky077.
    View in: PubMed
    Score: 0.051
  110. Calcium Intake and Survival after Colorectal Cancer Diagnosis. Clin Cancer Res. 2019 03 15; 25(6):1980-1988.
    View in: PubMed
    Score: 0.051
  111. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
    View in: PubMed
    Score: 0.050
  112. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120.
    View in: PubMed
    Score: 0.048
  113. Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol. 2018 Jan 01; 4(1):71-79.
    View in: PubMed
    Score: 0.048
  114. Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality. Gastroenterology. 2018 03; 154(4):916-926.e9.
    View in: PubMed
    Score: 0.047
  115. Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study. Int J Cancer. 2017 12 15; 141(12):2471-2479.
    View in: PubMed
    Score: 0.047
  116. Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). Gut. 2018 08; 67(8):1475-1483.
    View in: PubMed
    Score: 0.046
  117. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
    View in: PubMed
    Score: 0.046
  118. Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status. Eur J Epidemiol. 2017 05; 32(5):393-407.
    View in: PubMed
    Score: 0.046
  119. Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. Int J Cancer. 2017 06 15; 140(12):2648-2656.
    View in: PubMed
    Score: 0.045
  120. Periodontal disease, tooth loss and colorectal cancer risk: Results from the Nurses' Health Study. Int J Cancer. 2017 Feb 01; 140(3):646-652.
    View in: PubMed
    Score: 0.044
  121. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 10 18; 17(4):1206.
    View in: PubMed
    Score: 0.044
  122. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget. 2016 Aug 23; 7(34):55098-55109.
    View in: PubMed
    Score: 0.043
  123. Marine ?-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut. 2017 10; 66(10):1790-1796.
    View in: PubMed
    Score: 0.043
  124. Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer. 2016 08 15; 139(4):854-68.
    View in: PubMed
    Score: 0.043
  125. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 Apr 26; 15(4):857-865.
    View in: PubMed
    Score: 0.042
  126. Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. Br J Cancer. 2016 04 26; 114(9):995-1002.
    View in: PubMed
    Score: 0.042
  127. Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. Cancer Prev Res (Phila). 2015 Dec; 8(12):1138-45.
    View in: PubMed
    Score: 0.041
  128. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607.
    View in: PubMed
    Score: 0.040
  129. Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. Gastroenterology. 2015 Sep; 149(3):614-22.
    View in: PubMed
    Score: 0.040
  130. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345.
    View in: PubMed
    Score: 0.038
  131. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Ann Surg Oncol. 2014 Dec; 21(13):4164-73.
    View in: PubMed
    Score: 0.038
  132. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
    View in: PubMed
    Score: 0.031
  133. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009 Aug 04; 101(3):465-72.
    View in: PubMed
    Score: 0.027
  134. KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 May 20; 27(15_suppl):4037.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.